Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 5/20 | 0.55 |
| ▸ | AKR1C2 | P52895 | 5/20 | 0.55 |
| ▸ | PDK2 | Q15119 | 4/20 | 0.49 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.46 |
| ▸ | ADH5 | P11766 | 1/20 | 0.46 |
| ▸ | ERN1 | O75460 | 1/20 | 0.46 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.44 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.44 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.43 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.43 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27702486 | 0.87 | AKR1C3 (0.50) | AKR1C3AKR1C2PDK2FFAR2ADH5 | |
| SCHEMBL402398 | 0.87 | ADH5 (0.58) | AKR1C3AKR1C2PDK2FFAR2ADH5 | |
| SCHEMBL8183808 | 0.84 | MKNK1 (0.44) | AKR1C3AKR1C2PDK2MKNK1CHEK2 | |
| SCHEMBL17133900 | 0.84 | AKR1C3 (0.60) | AKR1C3AKR1C2PDK2FFAR2ADH5 | |
| SCHEMBL3089613 | 0.81 | S1PR1 (0.40) | AKR1C3AKR1C2FFAR2ADH5SRD5A2 | |
| SCHEMBL28192342 | 0.80 | PLK1 (0.57) | AKR1C3AKR1C2PDK2FFAR2S1PR1 | |
| SCHEMBL3903631 | 0.80 | EGFR (0.57) | AKR1C3AKR1C2PDK2SRD5A2S1PR1 | |
| SCHEMBL28098468 | 0.80 | MAPT (0.54) | AKR1C3AKR1C2FFAR2ADH5SRD5A2 | |
| SCHEMBL28022353 | 0.80 | FFAR2 (0.47) | AKR1C3AKR1C2FFAR2ADH5SRD5A2 | |
| SCHEMBL5131379 | 0.80 | PDK2 (0.49) | AKR1C3AKR1C2PDK2FFAR2CHEK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1826121-B | Application of phenyl and pyridyl derivatives in preparation of drugs for regulating calcium ion release and activating calcium ion channels | SYNTA PHARMACEUTICALS CORP | 2013-05-29 | — | — | CN | claimed |
| CN-102793692-A | Compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP | 2012-11-28 | — | — | CN | claimed |
| CN-101947218-A | The method of modulating calcium ion-release-activated calcium ion channels | SYNTA PHARMACEUTICALS CORP | 2011-01-19 | — | — | CN | claimed |
| CN-1826120-A | Compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP (US) | 2006-08-30 | — | — | CN | claimed |
| CN-1826121-A | Method for regulating and controlling calcium ion release to activate calcium ion channel | SYNTA PHARMACEUTICALS CORP (US) | 2006-08-30 | — | — | CN | claimed |
| CN-112409223-B | Amide compound and medical application thereof as STING inhibitor | 中国药科大学 | 2023-01-31 | — | — | CN | disclosed |
| CN-112409223-A | Amide compounds and medical application thereof as STING inhibitor | 中国药科大学 | 2021-02-26 | — | — | CN | disclosed |
| EP-2222669-B1 | OXADIAZOLE DERIVATIVES ACTIVE ON SPHINGOSINE-1-PHOSPHATE (SIP) | GLAXO GROUP LTD (GB) | 2013-08-21 | — | — | EP | disclosed |
| CN-1826121-B | Application of phenyl and pyridyl derivatives in preparation of drugs for regulating calcium ion release and activating calcium ion channels | SYNTA PHARMACEUTICALS CORP | 2013-05-29 | — | — | CN | disclosed |
| US-8324254-B2 | Oxadiazole substituted indazole derivatives for use as sphingosine 1-phosphate (S1P) agonists | GLAXO GROUP LIMITED (GB) | 2012-12-04 | — | — | US | disclosed |
| CN-102793692-A | Compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP | 2012-11-28 | — | — | CN | disclosed |
| US-8222245-B2 | Oxadiazole derivatives active on sphingosine-1-phosphate (S1P) | GLAXO GROUP LIMITED (GB) | 2012-07-17 | — | — | US | disclosed |
| WO-2010009508-A1 | ANTIPARASITIC COMPOUNDS | MURDOCH UNIVERSITY (AU) | 2010-01-28 | — | — | WO | disclosed |
| EP-2137181-A1 | OXADIAZOLE SUBSTITUTED INDAZOLE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE (S1P) AGONISTS | Glaxo Group Limited (GB) | 2009-12-30 | — | — | EP | disclosed |
| EP-2091949-A1 | INDOLE DERIVATIVES AS S1P1 RECEPTOR AGONISTS | Glaxo Group Limited (GB) | 2009-08-26 | — | — | EP | disclosed |
| WO-2009080725-A1 | OXADIAZOLE DERIVATIVES ACTIVE ON SPHINGOSINE-1-PHOSPHATE (SIP) | GLAXO GROUP LIMITED (GB) | 2009-07-02 | — | — | WO | disclosed |
| WO-2008128951-A1 | OXADIAZOLE SUBSTITUTED INDAZOLE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE (S1P) AGONISTS | GLAXO GROUP LIMITED (GB) | 2008-10-30 | — | — | WO | disclosed |
| WO-2008074821-A1 | INDOLE DERIVATIVES AS S1P1 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2008-06-26 | — | — | WO | disclosed |
| CN-1826121-A | Method for regulating and controlling calcium ion release to activate calcium ion channel | SYNTA PHARMACEUTICALS CORP (US) | 2006-08-30 | — | — | CN | disclosed |
| CN-1826120-A | Compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP (US) | 2006-08-30 | — | — | CN | disclosed |